Siltuximab to prevent severe side effects during immunotherapy rechallenge
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests if siltuximab can prevent severe immune-related side effects when patients restart immunotherapy (anti-PD-1/PD-L1) after previous severe side effects. It aims to make rechallenge safer for people with advanced cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have advanced cancer and your doctor thinks restarting immunotherapy may help
- You had a severe immune-related side effect from prior immunotherapy that required stopping treatment and high-dose steroids
- Your previous side effects have improved to mild or none
- You can take up to 10 mg of prednisone daily if needed
- Your blood counts and organ function are within certain limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving siltuximab before epcoritamab can help prevent or reduce cytokine release syndrome (a possible side effect where the immune system overreacts). It is for people with certain types of non-Hodgkin lymphoma that have not responded well to at least two prior treatments.
This trial tests a drug called siltuximab to see if it can help treat a type of lung rejection called antibody-mediated rejection (AMR) in people who have had a lung transplant. You may be eligible if you are currently hospitalized for AMR and are already planning to receive standard treatments.
This trial tests if the drug Siltuximab can help control side effects (CRS and ICANS) that sometimes happen after CAR-T treatment for multiple myeloma. It may help patients who develop these symptoms.
This trial tests a new combination of two drugs (sintilimab and anlotinib) for people with extensive-stage small cell lung cancer that has gotten worse after prior immunotherapy. The goal is to see if this combination can help control the cancer.
This trial studies adding an immunotherapy drug (sintilimab) to standard chemotherapy before surgery for resectable squamous non-small cell lung cancer. It aims to shrink the tumor and improve outcomes, while still keeping the cancer operable.
This trial tests a new combination therapy for people with advanced squamous non-small cell lung cancer. It adds sintilimab (an immunotherapy) and rh-endostatin (a drug that blocks blood supply to tumors) to standard chemotherapy, hoping to improve outcomes.
Hear when a new Hematopoietic and Lymphatic System Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.